Total Payments
$207,866
2024 Payments
$69,509
Companies
19
Transactions
141
Payment Breakdown by Category
Consulting$157,945 (76.0%)
Other$40,214 (19.3%)
Travel$6,903 (3.3%)
Food & Beverage$2,803 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $157,945 | 76 | 76.0% |
| Honoraria | $36,120 | 11 | 17.4% |
| Travel and Lodging | $6,903 | 21 | 3.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,094 | 4 | 2.0% |
| Food and Beverage | $2,803 | 29 | 1.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | $76,625 | 47 | $0 (2024) |
| Chiesi USA, Inc. | $59,827 | 34 | $0 (2024) |
| Agios Pharmaceuticals, Inc. | $44,311 | 28 | $0 (2024) |
| BIOVERATIV THERAPEUTICS INC. | $11,208 | 10 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $4,152 | 1 | $0 (2022) |
| bluebird bio, Inc. | $2,800 | 3 | $0 (2023) |
| Global Blood Therapeutics, Inc. | $2,178 | 3 | $0 (2022) |
| ModernaTX, Inc. | $2,125 | 2 | $0 (2021) |
| TerSera Therapeutics LLC | $1,597 | 3 | $0 (2024) |
| Halozyme Inc | $609.00 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $69,509 | 58 | Agios Pharmaceuticals, Inc. ($44,311) |
| 2023 | $53,921 | 40 | Chiesi USA, Inc. ($33,882) |
| 2022 | $42,316 | 19 | Vertex Pharmaceuticals Incorporated ($20,817) |
| 2021 | $20,428 | 9 | Vertex Pharmaceuticals Incorporated ($17,675) |
| 2020 | $10,485 | 5 | VERTEX PHARMACEUTICALS INCORPORATED ($5,950) |
| 2019 | $11,208 | 10 | BIOVERATIV THERAPEUTICS INC. ($11,208) |
All Payment Transactions
141 individual payment records from CMS Open Payments — Page 2 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/06/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $78.79 | General |
| Category: Genetically Defined Disease | ||||||
| 10/17/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $433.33 | General |
| 10/10/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $175.00 | General |
| 10/08/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 10/08/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| 10/02/2024 | Agios Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $94.88 | General |
| 09/26/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Honoraria | Cash or cash equivalent | $7,000.00 | General |
| Category: Genetically Defined Disease | ||||||
| 09/26/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Travel and Lodging | Cash or cash equivalent | $335.18 | General |
| Category: Genetically Defined Disease | ||||||
| 09/03/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $3,850.00 | General |
| 08/15/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $162.73 | General |
| Category: Hematology | ||||||
| 08/01/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $875.00 | General |
| 08/01/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $175.00 | General |
| 07/25/2024 | Chiesi USA, Inc. | FERRIPROX (Drug) | Honoraria | Cash or cash equivalent | $652.50 | General |
| Category: TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | ||||||
| 07/11/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $100.00 | General |
| Category: Genetically Defined Disease | ||||||
| 06/13/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $2,275.00 | General |
| 06/10/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| 05/21/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 05/16/2024 | Chiesi USA, Inc. | FERRIPROX (Drug) | Consulting Fee | Cash or cash equivalent | $3,480.00 | General |
| Category: TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | ||||||
| 04/30/2024 | PFIZER INC. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $244.69 | General |
| Category: HEMATOLOGY | ||||||
| 04/25/2024 | Chiesi USA, Inc. | FERRIPROX (Drug) | Honoraria | Cash or cash equivalent | $72.50 | General |
| Category: TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | ||||||
| 04/23/2024 | Chiesi USA, Inc. | FERRIPROX (Drug) | Honoraria | Cash or cash equivalent | $870.00 | General |
| Category: TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | ||||||
| 04/18/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $875.00 | General |
| 04/18/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 04/12/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| 04/12/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $175.00 | General |
About Dr. Sherif Badawy, MD
Dr. Sherif Badawy, MD is a Pediatric Hematology-Oncology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/18/2012. The National Provider Identifier (NPI) number assigned to this provider is 1821355660.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sherif Badawy, MD has received a total of $207,866 in payments from pharmaceutical and medical device companies, with $69,509 received in 2024. These payments were reported across 141 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($157,945).
Ad
Practice Information
- Specialty Pediatric Hematology-Oncology
- Other Specialties Pediatrics
- Location Chicago, IL
- Active Since 04/18/2012
- Last Updated 11/12/2025
- Taxonomy Code 2080P0207X
- Entity Type Individual
- NPI Number 1821355660
Products in Payments
- FERRIPROX (Drug) $54,449
- PYRUKYND (Drug) $44,216
- NO PRODUCT DISCUSSED (Drug) $11,208
- REBLOZYL (Biological) $4,315
- SKYSONA (Drug) $2,800
- OXBRYTA (Drug) $2,422
- XOLREMDI (Drug) $163.01
- Endari (Drug) $141.54
- Gamifant (Drug) $34.54
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Hematology-Oncology Doctors in Chicago
Alexis Thompson, Md, MD
Pediatric Hematology-Oncology — Payments: $1.6M
Pediatric Hematology-Oncology $1.6M
James Labelle
Pediatric Hematology-Oncology — Payments: $249,251
Pediatric Hematology-Oncology $249,251
Dr. Loretta Li, M.d, M.D
Pediatric Hematology-Oncology — Payments: $187,559
Pediatric Hematology-Oncology $187,559
Susan Cohn
Pediatric Hematology-Oncology — Payments: $125,685
Pediatric Hematology-Oncology $125,685
Leonard Valentino, M.d, M.D
Pediatric Hematology-Oncology — Payments: $117,453
Pediatric Hematology-Oncology $117,453
Dr. Miriam Bornhorst, Md, MD
Pediatric Hematology-Oncology — Payments: $69,696
Pediatric Hematology-Oncology $69,696